Autonomous rexinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells.
On their own, retinoid X receptor (RXR)-selective ligands (rexinoids) are silent in retinoic acid receptor (RAR)-RXR heterodimers, and no selective rexinoid program has been described as yet in cellular systems. We report here on the rexinoid signaling capacity that triggers apoptosis of immature promyelocytic NB4 cells as a default pathway in the absence of survival factors. Rexinoid-induced apoptosis displays all features of bona fide programmed cell death and is inhibited by RXR, but not RAR antagonists. Several types of survival signals block rexinoid-induced apoptosis. RARalpha agonists switch the cellular response toward differentiation and induce the expression of antiapoptosis factors. Activation of the protein kinase A pathway in the presence of rexinoid agonists induces maturation and blocks immature cell apoptosis. Addition of nonretinoid serum factors also blocks cell death but does not induce cell differentiation. Rexinoid-induced apoptosis is linked to neither the presence nor stability of the promyelocytic leukemia-RARalpha fusion protein and operates also in non-acute promyelocytic leukemia cells. Together our results support a model according to which rexinoids activate in certain leukemia cells a default death pathway onto which several other signaling paradigms converge. This pathway is entirely distinct from that triggered by RAR agonists, which control cell maturation and postmaturation apoptosis.
Benoit
G R
GR
INSERM U-496, Centre G. Hayem Hôpital Saint-Louis 75010 Paris, France.
Flexor
M
M
Besançon
F
F
Altucci
L
L
Rossin
A
A
Hillion
J
J
Balajthy
Z
Z
Legres
L
L
Ségal-Bendirdjian
E
E
Gronemeyer
H
H
Lanotte
M
M
D017209:Apoptosis / Q000187:drug effects*; D001769:Blood; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D003470:Culture Media; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D053938:DNA Fragmentation; D019281:Dimerization; D004351:Drug Resistance; D020287:In Situ Nick-End Labeling; D015473:Leukemia, Promyelocytic, Acute / Q000473:pathology*; D016328:NF-kappa B / Q000378:metabolism; D018168:Receptors, Retinoic Acid / Q000037:antagonists & inhibitors / Q000378:metabolism*; D047488:Retinoid X Receptors; D012176:Retinoids / Q000378:metabolism / Q000494:pharmacology*; D015398:Signal Transduction; D014157:Transcription Factors / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D003470:Culture Media; D016328:NF-kappa B; D018168:Receptors, Retinoic Acid; D047488:Retinoid X Receptors; D012176:Retinoids; D014157:Transcription Factors; D017868:Cyclic AMP-Dependent Protein Kinases